Pharma major Lupin announced today the successful completion of an inspection carried out by the USFDA at its Aurangabad, India facility. The inspection was carried out between February 10-14, 2020.
The inspection has concluded without any observation.
Commenting on the outcome of the inspection, Nilesh Gupta, Managing Director, Lupin said, “We are encouraged with the successful inspection at our Aurangabad facility. We continue to enhance our standards of quality and compliance across our manufacturing operations and remain committed to upholding the highest quality standards across all our sites”.
On Friday, the pharma company has also announced the launch of Moxifloxacin Ophthalmic Solution USP, 0.5%. It has received approval from the United States Food and Drug Administration (USFDA) earlier. The product would be manufactured at Lupin’s Pithampur (Unit-II) facility, India.
Lupin Ltd is currently trading at Rs721, up by Rs3.15 or 0.44% from its previous closing of Rs717.85 on the BSE.
The scrip opened at Rs717 and has touched a high and low of Rs724.75 and Rs713.05 respectively.
